Physician profile
Stuart J Andersen
NPI 1205270956
$1,213.84
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.91 · 2022: $625 · 2023: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $313.04 | 2022 | |
| Gilead Sciences, INC. | $258.71 | 2022-2023 | |
| Viiv Healthcare Company | $207.10 | 2022-2023 | Dovato, Apretude |
| Glaxosmithkline, LLC. | $109.33 | 2022-2023 | Bexsero |
| Lilly USA, LLC | $56.50 | 2022-2023 | Mounjaro |
| Emd Serono, INC. | $46.98 | 2022-2023 | Serostim |
| Merck Sharp & Dohme LLC | $43.00 | 2023 | Pifeltro, Delstrigo |
| Boston Scientific Corporation | $31.83 | 2023 | |
| Pfizer INC. | $30.73 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.83 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.91 | 2021 | |
| Phadia US INC. | $16.45 | 2023 | Immunocap |
| Novo Nordisk INC | $13.43 | 2023 | Wegovy, Saxenda |
| Tactile Systems Technology INC | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Andersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.